These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 21432875)

  • 1. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
    Masaki N; Koyama T; Yoshimura I; Hamada C
    J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On group sequential designs comparing two binomial proportions.
    Kepner JL
    J Biopharm Stat; 2010 Jan; 20(1):145-59. PubMed ID: 20077254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How a new stratified adaptive phase II design could improve targeting population.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Jun; 30(13):1555-62. PubMed ID: 21432892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An alternative phase II/III design for continuous endpoints.
    Huang WS; Liu JP; Hsiao CF
    Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of methods for adaptive treatment selection.
    Friede T; Stallard N
    Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A flexible design for multiple armed screening trials.
    Sargent DJ; Goldberg RM
    Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adaptive group sequential design for phase II/III clinical trials that select a single treatment from several.
    Kelly PJ; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):641-58. PubMed ID: 16022169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One- and two-stage designs for phase II window studies.
    Chang MN; Devidas M; Anderson J
    Stat Med; 2007 Jun; 26(13):2604-14. PubMed ID: 17211853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seamless Phase II/III combination study through response adaptive randomization.
    Wang L; Cui L
    J Biopharm Stat; 2007; 17(6):1177-87. PubMed ID: 18027224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.